Previous studies have shown that SMAD4 knockout or downregulation promotes 5-FU resistance in CRC models [89], suggesting that SMAD4 loss in MSS tumors may contribute to reduced drug sensitivity, consistent with experimental evidence [90]. This evidence concerns the gene SMAD4 and Marinesco-Sjogren syndrome.